| Summary of royalty and commercial payment receivable and contingent consideration activities |
The following table summarizes the royalty and commercial payment receivable activities under the cost recovery method during the year ended December 31, 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2025 |
|
|
Acquisition of Royalty and Commercial Payment Receivables |
|
|
Receipt of Royalty and Commercial Payments |
|
|
Reclassification of Royalty and Commercial Payment Receivables from the Cost Recovery to the EIR Method |
|
|
Balance as of December 31, 2025 |
Twist |
|
$ |
15,000 |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
15,000 |
Daré (XACIATO) |
|
|
21,999 |
|
|
— |
|
|
(6) |
|
|
— |
|
|
21,993 |
LadRx (MIPLYFFA) |
|
|
4,850 |
|
|
— |
|
|
(1,976) |
|
|
(2,874) |
|
|
— |
Palobiofarma |
|
|
10,000 |
|
|
— |
|
|
— |
|
|
— |
|
|
10,000 |
Kuros |
|
|
4,500 |
|
|
— |
|
|
— |
|
|
— |
|
|
4,500 |
Castle Creek |
|
|
— |
|
|
4,395 |
|
|
— |
|
|
— |
|
|
4,395 |
Total |
|
$ |
56,349 |
|
$ |
4,395 |
|
$ |
(1,982) |
|
$ |
(2,874) |
|
$ |
55,888 |
The following table summarizes the royalty and commercial payment receivable activities under the cost recovery method during the year ended December 31, 2024 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2024 |
|
|
Acquisition of Royalty and Commercial Payment Receivables |
|
|
Receipt of Royalty and Commercial Payments |
|
|
Recognition of Contingent Consideration |
|
|
Credit Losses on Purchased Receivables |
|
|
Reclassification of Royalty and Commercial Payment Receivables from the Cost Recovery to the EIR Method |
|
|
Balance as of December 31, 2024 |
Twist |
|
$ |
— |
|
$ |
15,000 |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
15,000 |
Daré |
|
|
— |
|
|
22,000 |
|
|
(1) |
|
|
— |
|
|
— |
|
|
— |
|
|
21,999 |
Talphera |
|
|
— |
|
|
8,000 |
|
|
(96) |
|
|
— |
|
|
(7,904) |
|
|
— |
|
|
— |
LadRx |
|
|
6,000 |
|
|
— |
|
|
(2,150) |
|
|
1,000 |
|
|
— |
|
|
— |
|
|
4,850 |
Aptevo |
|
|
7,976 |
|
|
— |
|
|
(795) |
|
|
— |
|
|
— |
|
|
(7,181) |
|
|
— |
Agenus |
|
|
14,000 |
|
|
— |
|
|
— |
|
|
— |
|
|
(14,000) |
|
|
— |
|
|
— |
Aronora |
|
|
9,000 |
|
|
— |
|
|
— |
|
|
— |
|
|
(9,000) |
|
|
— |
|
|
— |
Palobiofarma |
|
|
10,000 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
10,000 |
Viracta |
|
|
8,500 |
|
|
— |
|
|
(8,500) |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Kuros |
|
|
4,500 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
4,500 |
Affitech |
|
|
12,191 |
|
|
— |
|
|
(7,396) |
|
|
3,000 |
|
|
— |
|
|
(7,795) |
|
|
— |
Total |
|
$ |
72,167 |
|
$ |
45,000 |
|
$ |
(18,938) |
|
$ |
4,000 |
|
$ |
(30,904) |
|
$ |
(14,976) |
|
$ |
56,349 |
The following table summarizes the royalty and commercial payment receivable activities under the EIR method during the year ended December 31, 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2025 |
|
Reclassification of Royalty and Commercial Payment Receivables from the Cost Recovery to the EIR Method |
|
Income from Purchased Receivables Under the EIR Method |
|
Receipt of Royalty and Commercial Payments |
|
Payment of Sales-Based Milestone |
|
|
Balance as of December 31, 2025 |
Affitech (VABYSMO) |
|
$ |
13,105 |
|
$ |
— |
|
$ |
23,957 |
|
$ |
(22,507) |
|
$ |
3,000 |
|
$ |
17,555 |
Aptevo (IXINITY) |
|
|
6,628 |
|
|
— |
|
|
989 |
|
|
(1,724) |
|
|
— |
|
|
5,893 |
LadRx (MIPLYFFA) |
|
|
— |
|
|
2,874 |
|
|
1,799 |
|
|
(908) |
|
|
— |
|
|
3,765 |
Total |
|
$ |
19,733 |
|
$ |
2,874 |
|
$ |
26,745 |
|
$ |
(25,139) |
|
$ |
3,000 |
|
$ |
27,213 |
The following table summarizes the royalty and commercial payment receivable activities under the EIR method during the year ended December 31, 2024 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2024 |
|
|
Reclassification of Royalty and Commercial Payment Receivables from the Cost Recovery to the EIR Method |
|
|
Income from Purchased Receivables Under the EIR Method |
|
|
Receipt of Royalty and Commercial Payments |
|
|
Balance as of December 31, 2024 |
Affitech |
|
$ |
— |
|
$ |
7,795 |
|
$ |
14,800 |
|
$ |
(9,490) |
|
$ |
13,105 |
Aptevo |
|
|
— |
|
|
7,181 |
|
|
266 |
|
|
(819) |
|
|
6,628 |
Total |
|
$ |
— |
|
$ |
14,976 |
|
$ |
15,066 |
|
$ |
(10,309) |
|
$ |
19,733 |
|